---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-098225"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:59:46.484711+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics issues 27,316 common shares upon conversion of Series C and D preferred stock

## Summary
- 4,138 Series C shares converted into 1,086 common shares at $30.50 per share.
- 100,000 Series D shares converted into 26,230 common shares at $30.50 per share.
- Total 27,316 common shares issued; no Series C or D preferred shares remain outstanding.

## SEC filing metadata
- accession: 0001104659-24-098225
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924098225/0001104659-24-098225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924098225/tm2423567d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-098225
- JSON: https://secwatch.observer/filing/0001104659-24-098225.json
- Plain text: https://secwatch.observer/filing/0001104659-24-098225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.